Browsing Tag
zanidatamab
2 posts
Zymeworks (ZYME) to buy Theravance (TBPH) for $929m in cash plus ampreloxetine CVR
Zymeworks (ZYME) to acquire Theravance (TBPH) for $17/share plus CVR, $929M equity value. Non-recourse OMERS financing minimises ZYME's cash at risk.
Jazz Pharmaceuticals’ zanidatamab shows promising results in HER2-positive biliary tract cancer
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has released pivotal new data from its Phase 2b HERIZON-BTC-01 clinical trial assessing…